Citius Pharmaceuticals Reaches 92 Event Milestone In Mino-Lok Phase 3 Trial
Portfolio Pulse from Benzinga Newsdesk
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has announced reaching a significant milestone in its Phase 3 clinical trial for Mino-Lok, an antibiotic lock solution for patients with catheter-related bloodstream infections. The company believes all 92 events required to complete the trial have been achieved, pending confirmation from an independent review committee. The trial is being conducted in the U.S. and India, with several patients still in active treatment.
August 10, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citius Pharmaceuticals has reached a significant milestone in its Phase 3 trial for Mino-Lok. This could potentially bring the company closer to the commercialization of the product, which may positively impact the company's stock.
The achievement of a significant milestone in a clinical trial is generally seen as a positive development for a pharmaceutical company. This could potentially bring Citius Pharmaceuticals closer to the commercialization of Mino-Lok, which could have a positive impact on the company's revenues and, consequently, its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100